La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Pierrel Résultats passés
Passé contrôle des critères 4/6
Pierrel has been growing earnings at an average annual rate of 7.3%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 4.4% per year. Pierrel's return on equity is 12.1%, and it has net margins of 11.5%.
Informations clés
7.3%
Taux de croissance des bénéfices
-17.0%
Taux de croissance du BPA
Pharmaceuticals Croissance de l'industrie | 12.4% |
Taux de croissance des recettes | 4.4% |
Rendement des fonds propres | 12.1% |
Marge nette | 11.5% |
Dernière mise à jour des bénéfices | 30 Jun 2023 |
Mises à jour récentes des performances passées
Recent updates
We Think Pierrel (BIT:PRL) Can Stay On Top Of Its Debt
May 26Does Pierrel (BIT:PRL) Have A Healthy Balance Sheet?
Aug 11Here's Why Pierrel (BIT:PRL) Has A Meaningful Debt Burden
Apr 05Introducing Pierrel (BIT:PRL), A Stock That Climbed 76% In The Last Year
Mar 10Calculating The Fair Value Of Pierrel S.p.A. (BIT:PRL)
Feb 10How Is Pierrel's (BIT:PRL) CEO Paid Relative To Peers?
Dec 30These 4 Measures Indicate That Pierrel (BIT:PRL) Is Using Debt Extensively
Dec 01Ventilation des recettes et des dépenses
Comment Pierrel gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
---|---|---|---|---|
30 Jun 23 | 27 | 3 | 7 | 0 |
31 Mar 23 | 25 | 1 | 7 | 0 |
31 Dec 22 | 24 | 1 | 7 | 0 |
30 Sep 22 | 25 | 1 | 7 | 0 |
30 Jun 22 | 24 | 2 | 7 | 0 |
31 Mar 22 | 23 | 3 | 7 | 0 |
31 Dec 21 | 24 | 3 | 7 | 0 |
30 Sep 21 | 21 | 3 | 6 | 0 |
30 Jun 21 | 19 | 1 | 6 | 0 |
31 Mar 21 | 21 | 3 | 6 | 0 |
31 Dec 20 | 18 | 2 | 6 | 0 |
30 Sep 20 | 20 | 3 | 6 | 0 |
30 Jun 20 | 23 | 4 | 6 | 0 |
31 Mar 20 | 21 | 2 | 6 | 0 |
31 Dec 19 | 22 | 2 | 6 | 0 |
30 Sep 19 | 22 | 1 | 6 | 0 |
30 Jun 19 | 21 | 1 | 6 | 0 |
31 Mar 19 | 21 | 1 | 6 | 0 |
31 Dec 18 | 20 | 1 | 6 | 0 |
30 Sep 18 | 21 | 2 | 6 | 0 |
30 Jun 18 | 20 | 2 | 6 | 0 |
31 Mar 18 | 19 | 0 | 5 | 0 |
31 Dec 17 | 17 | -3 | 5 | 0 |
30 Sep 17 | 15 | -8 | 5 | 0 |
30 Jun 17 | 14 | -9 | 5 | 0 |
31 Mar 17 | 14 | -8 | 5 | 0 |
31 Dec 16 | 15 | -6 | 5 | 0 |
30 Sep 16 | 14 | -2 | 6 | 0 |
30 Jun 16 | 14 | -1 | 6 | 0 |
31 Mar 16 | 15 | 0 | 6 | 0 |
31 Dec 15 | 16 | 0 | 6 | 0 |
30 Sep 15 | 5 | 10 | -2 | 0 |
30 Jun 15 | 8 | 6 | 0 | 0 |
31 Mar 15 | 13 | 0 | 3 | 0 |
31 Dec 14 | 15 | -2 | 6 | 0 |
30 Sep 14 | 30 | -16 | 17 | 0 |
30 Jun 14 | 29 | -16 | 17 | 0 |
31 Mar 14 | 29 | -12 | 17 | 0 |
31 Dec 13 | 30 | -13 | 17 | 0 |
30 Sep 13 | 30 | -14 | 18 | 0 |
30 Jun 13 | 36 | -12 | 18 | 0 |
31 Mar 13 | 40 | -13 | 19 | 0 |
Des revenus de qualité: PRL has a large one-off gain of €741.2K impacting its last 12 months of financial results to 30th June, 2023.
Augmentation de la marge bénéficiaire: PRL's current net profit margins (11.5%) are higher than last year (7.5%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: PRL has become profitable over the past 5 years, growing earnings by 7.3% per year.
Accélération de la croissance: PRL's earnings growth over the past year (75.3%) exceeds its 5-year average (7.3% per year).
Bénéfices par rapport au secteur d'activité: PRL earnings growth over the past year (75.3%) exceeded the Pharmaceuticals industry 3.7%.
Rendement des fonds propres
ROE élevé: PRL's Return on Equity (12.1%) is considered low.